Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors

Pediatr Dermatol. 2024 Nov-Dec;41(6):1040-1046. doi: 10.1111/pde.15721. Epub 2024 Sep 5.

Abstract

Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for transducing cytokine signals. The first JAKi was approved by the US Food and Drug Administration (FDA) in 2011 to treat rheumatoid arthritis in adults. A pediatric indication was not approved until 8 years later, for acute graft-versus-host disease. Since then, topical and oral formulations have gained FDA approval for pediatric patients with dermatologic diseases. While increasing evidence supports the safety of these medications in adults, data are limited in children. We sought to determine whether JAKi adverse events (AEs) as reported in clinical trials and via postapproval pharmacovigilance services are comparable in adult and pediatric patients. Pharmacovigilance data were extracted from the FDA's Adverse Event Reporting System and the Canada Vigilance Adverse Reaction Online Database for baricitinib, upadacitinib, abrocitinib, ruxolitinib, and tofacitinib. The pooled data were analyzed to detect the most common AEs for specific JAKi and for the drug class. We assessed 399,649 AEs from 133,216 adults and 2883 AEs from 955 patients under 18 years old and identified slightly different AE profiles for the two age groups. Both populations had increased risk for infections and gastrointestinal AEs. However, pediatric patients reported a higher proportion of blood and lymphatic disorders, while reports of nervous system and musculoskeletal/connective tissue disorders were more common in adults. The spectrum of AEs extracted from pharmacovigilance reports was similar to clinical trials. The JAKi AE profiles we observed may prove helpful in counseling patients and their parents before starting therapy and for monitoring once patients are on therapy.

Keywords: Janus kinase inhibitors; adverse event; dermatology; pediatrics; skin diseases.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adverse Drug Reaction Reporting Systems* / statistics & numerical data
  • Azetidines / adverse effects
  • Canada
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Janus Kinase Inhibitors* / adverse effects
  • Janus Kinase Inhibitors* / therapeutic use
  • Male
  • Nitriles / adverse effects
  • Nitriles / therapeutic use
  • Pharmacovigilance*
  • Piperidines* / adverse effects
  • Piperidines* / therapeutic use
  • Purines / adverse effects
  • Purines / therapeutic use
  • Pyrazoles* / adverse effects
  • Pyrazoles* / therapeutic use
  • Pyrimidines* / adverse effects
  • Pyrimidines* / therapeutic use
  • Pyrroles / adverse effects
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • United States
  • United States Food and Drug Administration

Substances

  • abrocitinib
  • Azetidines
  • baricitinib
  • Janus Kinase Inhibitors
  • Nitriles
  • Piperidines
  • Purines
  • Pyrazoles
  • Pyrimidines
  • Pyrroles
  • ruxolitinib
  • Sulfonamides
  • tofacitinib
  • upadacitinib